The objective of the study is to determine the number/percent of patients with colorectal carcinoma who respond or show stabilization of their disease.

Condition	Treatment or Intervention	Phase
Colorectal Neoplasm Carcinoma, Renal Cell	Drug: BAY 43-9006	Phase II

Ages Eligible for Study:  18 Years   -   75 Years,  Genders Eligible for Study:  Both

Criteria

This study is completed.

Inclusion Criteria:

• Age 18 year and older.
• Patients with refractory solid cancer for which curative or palliative measures have failed or patients whose treatments are considered ineffective or intolerable.
• Patients with non-colorectal cancers are eligible and must be progressing at the time of the screening assessment and for whom no other treatment exists.
• Histological or cytological documentation of cancer
• ECOG performance status of 0 or 1.
• Life-expectancy of at least 12 weeks
• Adequate bone marrow, liver function, and renal function.

Exclusion Criteria:

Patients who meet the following criteria at the time of screening will be excluded:

Excluded medical conditions:

• NSCLC, Hepatocellular carcinoma, CML, AML
• Serious cardiac arrhythmia
• Congestive Heart Failure
• Active coronary artery disease or ischemia
• Active acute infections that could be worsened by anticancer therapy or interfere with this study.
• Known HIV infection

Illinois
      University of Chicago Medical Center, Chicago,  Illinois,  60064,  United States

Study ID Numbers:  100391
Record last reviewed:  November 2004
Record first received:  March 9, 2004
ClinicalTrials.gov Identifier:  NCT00079612
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2004-11-10